Detail page

Knowledge Web

Person

Daniel Michaeli (1997-)

Arzt

Name	Daniel Michaeli
Time	1997- (Date of birth and death)
Place	Deutschland
Gender	männlich
Academic degree	Dr. med. (Medizinische Fakultät Mannheim der Universität Heidelberg) (2024) Dr. rer. oec.
Profession	Arzt (characteristic profession) Wirtschaftswissenschaftler
Variant	Daniel T. Michaeli Daniel Tobias Michaeli D. T. Michaeli
Related	Nationales Centrum für Tumorerkrankungen (2023-) Krebsforschung (Thema)
Further information	Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.- TUM School of Management, Technical University of Munich, Munich, Germany.- Promotion Bergische Universität Wuppertal 2024 an der Schumpeter School of Economics.- Schwerpunkte: Onkologie, Krebsmedikamente.-
Source	https://www.linkedin.com/in/daniel-michaeli/?originalSubdomain=de (Stand: 26.09.2024)
Record type	Person
GND-Identifier	1277183244
Record ID	1277183244
Involved in show all Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries Economics of cancer drugs : development, approval, benefit, trials, innovation, value, price, and competition Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa Value drivers of development stage biopharma companies Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany Testicular cancer follow-up costs in Germany from 2000 to 2015 Prostate cancer follow-up costs in Germany from 2000 to 2015

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Daniel Michaeli (1997-)

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition

Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries

Economics of cancer drugs : development, approval, benefit, trials, innovation, value, price, and competition

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy

Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa

Value drivers of development stage biopharma companies

Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany

Testicular cancer follow-up costs in Germany from 2000 to 2015

Prostate cancer follow-up costs in Germany from 2000 to 2015